Profile data is unavailable for this security.
About the company
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
- Revenue in USD (TTM)0.00
- Net income in USD-57.95m
- Incorporated2020
- Employees50.00
- LocationLongboard Pharmaceuticals Inc4275 Executive Square, Suite 950LA JOLLA 92037United StatesUSA
- Phone+1 (619) 592-9775
- Fax+1 (302) 636-5454
- Websitehttps://www.longboardpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | 68.00k | -228.34m | 706.18m | 224.00 | -- | 1.17 | -- | 10,385.02 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Regenxbio Inc | 86.73m | -260.15m | 706.82m | 344.00 | -- | 1.80 | -- | 8.15 | -5.88 | -5.88 | 1.96 | 7.97 | 0.126 | -- | 5.00 | 252,110.50 | -37.78 | -16.75 | -45.07 | -19.08 | 56.89 | 78.27 | -299.97 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Phibro Animal Health Corp | 999.56m | 13.16m | 714.08m | 1.92k | 54.27 | 2.64 | 14.66 | 0.7144 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| Pliant Therapeutics Inc | 248.00k | -170.74m | 731.75m | 158.00 | -- | 1.67 | -- | 2,950.61 | -2.86 | -2.86 | 0.0042 | 7.25 | 0.0004 | -- | 0.0701 | 1,569.62 | -30.50 | -33.24 | -32.04 | -35.39 | -- | -- | -68,847.98 | -360.29 | -- | -- | 0.0642 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| GH Research PLC | 0.00 | -35.59m | 733.08m | 49.00 | -- | 3.35 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 733.67m | 50.00 | -- | 2.34 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 739.38m | 140.00 | -- | 2.79 | -- | 19.86 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -121.21m | 748.14m | 116.00 | -- | 2.00 | -- | -- | -2.91 | -2.91 | 0.00 | 9.48 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -183.26m | 748.89m | 150.00 | -- | 4.10 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Wave Life Sciences Ltd | 112.91m | -61.67m | 756.80m | 266.00 | -- | 29.77 | -- | 6.70 | -0.5152 | -0.5152 | 0.9985 | 0.2719 | 0.4494 | -- | -- | 424,488.70 | -24.54 | -56.98 | -60.43 | -102.38 | -- | -- | -54.61 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Stoke Therapeutics Inc | 7.85m | -108.53m | 761.99m | 110.00 | -- | 4.84 | -- | 97.13 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Viridian Therapeutics Inc | 288.00k | -218.13m | 762.68m | 96.00 | -- | 1.99 | -- | 2,648.19 | -4.50 | -4.50 | 0.0058 | 9.13 | 0.0006 | -- | 2.50 | 3,063.83 | -42.89 | -55.59 | -45.38 | -60.32 | -- | -- | -75,737.84 | -5,678.12 | -- | -- | 0.0337 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Cogent Biosciences Inc | 0.00 | -212.17m | 765.86m | 164.00 | -- | 3.83 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Nuvation Bio Inc | 0.00 | -68.87m | 766.23m | 159.00 | -- | 1.14 | -- | -- | -0.3146 | -0.3146 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -10.84 | -16.27 | -11.09 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 775.17m | 300.00 | -- | 2.17 | -- | 4.05 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| 89bio Inc | 0.00 | -165.03m | 777.23m | 70.00 | -- | 1.47 | -- | -- | -2.01 | -2.01 | 0.00 | 5.36 | 0.00 | -- | -- | 0.00 | -30.80 | -45.50 | -32.70 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
Data as of May 31 2024. Currency figures normalised to Longboard Pharmaceuticals Inc's reporting currency: US Dollar USD
72.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 4.52m | 13.47% |
| Cormorant Asset Management LPas of 31 Mar 2024 | 3.35m | 9.98% |
| RA Capital Management LPas of 31 Mar 2024 | 3.29m | 9.79% |
| Farallon Capital Management LLCas of 31 Mar 2024 | 2.94m | 8.75% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.20m | 6.56% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 2.14m | 6.36% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.67m | 4.98% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.65m | 4.91% |
| Point72 Asset Management LPas of 31 Mar 2024 | 1.38m | 4.10% |
| Polar Capital LLPas of 31 Mar 2024 | 1.31m | 3.89% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
